Pretreatment With P2Y12 Inhibitors in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the Swedish Coronary Angiography and Angioplasty Registry
| Autor: | David Erlinge, Johan Nilsson, Tomas Jernberg, Linda Mellbin, Sebastian Völz, C Lewinter, Matthias Götberg, Dimitrios Venetsanos, Elmir Omerovic, Jonas Persson, Sammy Zwackman, K. Szummer, Juliane Jurga |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Coronary angiography
medicine.medical_specialty medicine.medical_treatment Coronary Angiography P2Y12 Percutaneous Coronary Intervention Internal medicine Angioplasty Medicine Humans In patient Registries Acute Coronary Syndrome Sweden business.industry Percutaneous coronary intervention Odds ratio Clopidogrel Treatment Outcome Cardiology Purinergic P2Y Receptor Antagonists Cardiology and Cardiovascular Medicine business Ticagrelor Prasugrel Hydrochloride Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Circulation. Cardiovascular interventions. 14(11) |
| ISSN: | 1941-7632 |
| Popis: | Background: In patients with chronic coronary syndrome undergoing percutaneous coronary intervention, the optimal timing of P2Y12 inhibitors’ administration is uncertain. We compared pretreatment versus treatment in the catheterization laboratory (In-Cathlab) in a real-world population. Methods: In Swedish Coronary Angiography and Angioplasty Registry, all patients with chronic coronary syndrome undergoing coronary angiography and ad hoc percutaneous coronary intervention, between 2006 and 2017 were identified. Pretreatment was defined as P2Y12 inhibitor administration before coronary angiography, outside the catheterization laboratory. Outcomes were net adverse clinical events including death, myocardial infarction, stroke, or bleeding within 30 days of the index procedure and in-hospital bleeding. Results: We included 26 814 patients, 8237 in the In-Cathlab, and 18 577 in the pretreatment group. In-Cathlab treatment compared with pretreatment was associated with lower risk for net adverse clinical event (4.2 versus 5.1%, adjusted hazard ratio 0.79 [0.63–0.99]), bleeding (2.3 versus 2.6%, adjusted hazard ratio, 0.76 [0.57–1.01]). and in-hospital bleeding (1.9 versus 2.1%, adjusted odds ratio, 0.70 [0.51–0.96]). The risk for death, myocardial infarction, or stroke did not significantly differ between the groups. Among the In-Cathlab treated patients, 41% received ticagrelor or prasugrel and 59% clopidogrel. Treatment with ticagrelor or prasugrel was associated with higher risk for net adverse clinical events (5.4% versus 3.4%, adjusted hazard ratio, 1.66 [1.12–2.48]), bleeding (3.4 versus 1.6%, adjusted hazard ratio, 2.14 [1.34–3.42]), and in-hospital bleeding (2.9 versus 1.2%, adjusted odds ratio, 2.24 [1.29–3.90]) but similar risk for death, myocardial infarction, or stroke, compared with clopidogrel. Conclusions: In patients with chronic coronary syndrome undergoing coronary angiography and ad hoc percutaneous coronary intervention, pretreatment with P2Y12 inhibitors, before arrival to the catheterization laboratory, was not associated with improved clinical outcomes but was associated with increased risk for bleeding. Our data support clopidogrel administration in the catheterization laboratory as the standard of care. Graphic Abstract: A graphic abstract is available for this article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|